WO2002043759A3 - Method and composition for modulating bone growth - Google Patents
Method and composition for modulating bone growth Download PDFInfo
- Publication number
- WO2002043759A3 WO2002043759A3 PCT/US2001/046291 US0146291W WO0243759A3 WO 2002043759 A3 WO2002043759 A3 WO 2002043759A3 US 0146291 W US0146291 W US 0146291W WO 0243759 A3 WO0243759 A3 WO 0243759A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- compositions
- bone growth
- modulating bone
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002236558A AU2002236558A1 (en) | 2000-12-01 | 2001-12-03 | Method and composition for modulating bone growth |
EP01986092A EP1370287A2 (en) | 2000-12-01 | 2001-12-03 | Method and composition for modulating bone growth |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25053500P | 2000-12-01 | 2000-12-01 | |
US60/250,535 | 2000-12-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002043759A2 WO2002043759A2 (en) | 2002-06-06 |
WO2002043759A3 true WO2002043759A3 (en) | 2003-10-09 |
Family
ID=22948150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/046291 WO2002043759A2 (en) | 2000-12-01 | 2001-12-03 | Method and composition for modulating bone growth |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1370287A2 (en) |
AU (1) | AU2002236558A1 (en) |
WO (1) | WO2002043759A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9572865B2 (en) | 2005-11-23 | 2017-02-21 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating multiple myeloma |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5906827A (en) † | 1994-06-03 | 1999-05-25 | Creative Biomolecules, Inc. | Matrix for the manufacture of autogenous replacement body parts |
AU6267798A (en) † | 1997-02-07 | 1998-08-26 | Stryker Corporation | Matrix-free osteogenic devices, implants and methods of use thereof |
DK1223990T3 (en) | 1999-10-15 | 2004-11-29 | Inst Genetics Llc | Formulations of hyaluronic acid for delivery of osteogenic proteins |
US7625867B2 (en) * | 2004-03-26 | 2009-12-01 | Acceleron Pharma Inc. | BMP-3 propeptides and related methods |
US7741284B2 (en) | 2004-05-12 | 2010-06-22 | Acceleron Pharma Inc. | BMP10 propeptides and related methods |
CA2572330A1 (en) | 2004-06-24 | 2006-01-05 | Acceleron Pharma Inc. | Gdf3 propeptides and related methods |
US7709605B2 (en) | 2004-07-23 | 2010-05-04 | Acceleron Pharma Inc. | ActRII receptor polypeptides, methods and compositions |
US20060115462A1 (en) * | 2004-12-01 | 2006-06-01 | Vladimir Subbotin | Direct DNA delivery to bone cells |
EP1885749B1 (en) | 2005-05-27 | 2017-08-23 | BBS-Bioactive Bone Substitutes Oy | Bone morphogenetic protein 3 and osteogenic devices and pharmaceutical products containing thereof |
CN105001320A (en) | 2005-11-23 | 2015-10-28 | 阿塞勒隆制药公司 | Activin-ActRIIa antagonists and uses for promoting bone growth |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
WO2007123896A2 (en) | 2006-04-18 | 2007-11-01 | The Trustees Of The University Of Pennsylvania | Mutated acvr1 for diagnosis and treatment of fibrodyplasia ossificans progressiva (fop) |
US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
KR101831534B1 (en) | 2006-12-18 | 2018-02-22 | 악셀레론 파마 인코포레이티드 | Activin-actrii antagonists and uses for increasing red blood cell levels |
ES2415666T3 (en) | 2007-02-01 | 2013-07-26 | Acceleron Pharma, Inc. | Pharmaceutical compositions comprising Activin-ActRIIa antagonists for use in the prevention or treatment of breast cancer metastases or bone loss related to breast cancer |
TW201940502A (en) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | Variants derived from ActRIIB and uses therefor |
EP3243524A1 (en) | 2007-09-18 | 2017-11-15 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
PT3750552T (en) | 2008-08-14 | 2023-06-28 | Acceleron Pharma Inc | Gdf traps |
WO2010083034A1 (en) | 2009-01-13 | 2010-07-22 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
AU2010258931B2 (en) | 2009-06-08 | 2015-04-23 | Acceleron Pharma Inc. | Methods for increasing thermogenic adipocytes |
MX2011013364A (en) | 2009-06-12 | 2012-03-16 | Acceleron Pharma Inc | Truncated actriib-fc fusion proteins. |
JP6267425B2 (en) | 2009-11-17 | 2018-01-24 | アクセルロン ファーマ, インコーポレイテッド | ACTRIIB protein and its variants and uses thereof for utrophin induction for the treatment of muscular dystrophy |
EP2638065A4 (en) | 2010-11-08 | 2014-04-09 | Acceleron Pharma Inc | Actriia binding agents and uses thereof |
KR102279522B1 (en) | 2012-11-02 | 2021-07-19 | 셀진 코포레이션 | Activin-actrii antagonists and uses for treating bone and other disorders |
TN2016000553A1 (en) | 2014-06-13 | 2018-04-04 | Acceleron Pharma Inc | Methods and compositions for treating ulcers |
MA41052A (en) | 2014-10-09 | 2017-08-15 | Celgene Corp | TREATMENT OF CARDIOVASCULAR DISEASE USING ACTRII LIGAND TRAPS |
WO2016090077A1 (en) | 2014-12-03 | 2016-06-09 | Celgene Corporation | Activin-actrii antagonists and uses for treating anemia |
JP2020502218A (en) | 2016-12-21 | 2020-01-23 | メレオ バイオファーマ 3 リミテッド | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5116738A (en) * | 1986-07-01 | 1992-05-26 | Genetics Institute, Inc. | DNA sequences encoding |
US5393739A (en) * | 1990-11-30 | 1995-02-28 | Celtrix Pharmaceuticals, Inc. | Use of bone morphogenetic protein in synergistic combination with TGF-β for bone repair |
-
2001
- 2001-12-03 EP EP01986092A patent/EP1370287A2/en not_active Withdrawn
- 2001-12-03 WO PCT/US2001/046291 patent/WO2002043759A2/en not_active Application Discontinuation
- 2001-12-03 AU AU2002236558A patent/AU2002236558A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5116738A (en) * | 1986-07-01 | 1992-05-26 | Genetics Institute, Inc. | DNA sequences encoding |
US5393739A (en) * | 1990-11-30 | 1995-02-28 | Celtrix Pharmaceuticals, Inc. | Use of bone morphogenetic protein in synergistic combination with TGF-β for bone repair |
Non-Patent Citations (4)
Title |
---|
FAUCHEUX C ET AL: "Effect of 1,25(OH)2D3 on bone morphogenetic protein-3 mRNA expression.", JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 73, no. 1, 1 April 1999 (1999-04-01), pages 11 - 19, XP002224340, ISSN: 0730-2312 * |
FAUCHEUX C ET AL: "Opposing actions of BMP3 and TGFbeta1 in human bone marrow stromal cell growth and differentiation.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 241, no. 3, 29 December 1997 (1997-12-29), pages 787 - 793, XP002224339, ISSN: 0006-291X * |
See also references of EP1370287A2 * |
THOMADAKIS GEORGIOS ET AL: "Immunolocalization of Bone Morphogenetic Protein-2 and -3 and Osteogenic Protein-1 during murine tooth root morphogenesis and in other craniofacial structures.", EUROPEAN JOURNAL OF ORAL SCIENCES, vol. 107, no. 5, October 1999 (1999-10-01), pages 368 - 377, XP001127481, ISSN: 0909-8836 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9572865B2 (en) | 2005-11-23 | 2017-02-21 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating multiple myeloma |
Also Published As
Publication number | Publication date |
---|---|
EP1370287A2 (en) | 2003-12-17 |
WO2002043759A2 (en) | 2002-06-06 |
AU2002236558A1 (en) | 2002-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002043759A3 (en) | Method and composition for modulating bone growth | |
DE69936102D1 (en) | USE OF TNF-ALPHA INHIBITORS FOR THE TREATMENT OF NERVE ROOT DAMAGE | |
MXPA04001334A (en) | Materials and methods to promote repair of nerve tissue. | |
MY141384A (en) | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | |
WO1998058911A3 (en) | Prostaglandin agonists | |
NO20075801L (en) | Method of treating or preventing bone destruction or osteoporosis | |
WO2005037259A3 (en) | Methods and compositions for the prevention or treatment of neoplasia comprising a cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist | |
WO2002100331A3 (en) | Calcium phosphate delivery vehicles for osteoinductive proteins | |
WO2005094871A3 (en) | Bmp-3 propeptides and related methods | |
WO2002010348A3 (en) | Tissue implant for cartilage repair | |
WO2003053340A3 (en) | Antisense modulation of connective tissue growth factor expression | |
ATE492275T1 (en) | VITAMIN K FOR PREVENTING AND TREATING SKIN RASH AS A RESULT OF ANTI-EGFR THERAPY | |
EP1205189A3 (en) | Combination of a prostaglandin agonist and a HMG-CoA reductase inhibitor for the stimulation of bone growth | |
AU2002258592A1 (en) | Compositions and methods for modulating bone mineral deposition | |
ATE394124T1 (en) | METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR MODULATING BONE GROWTH | |
WO2004064832A3 (en) | Methods for treating joint pain or improving sleep using an estrogen agonist/antagonist | |
AU2003233735A1 (en) | 24-sulfoximine vitamin d3 compounds | |
WO2004006833A3 (en) | Bowel cleansing composition | |
WO2004032908A3 (en) | Method of inhibiting angiogenesis | |
WO2003034987A3 (en) | Androgen receptor modulators and methods of use thereof | |
DE60143034D1 (en) | OPTICALLY PURE (-) CLETHODIM, AS WELL AS THESE COMPOSITIONS AND METHOD FOR CONTROLLING PLANT GROWTH | |
WO2003051220A3 (en) | Device and method for bone formation by distraction of bone segments | |
CY1110156T1 (en) | Substituted Compounds 4,5,6,7-tetrahydro-benzothiiazol-2-ylamine | |
WO2003059277A3 (en) | Methods and compositions for stimulating bone growth using inhibitors of microtubule assembly | |
AU2003287669A1 (en) | Composition and method for mammary disinfection during winter conditions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2001986092 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2001986092 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |